SCARLET® AC-T Secured Anterior Cervical Cage

K190322 · Spineart · ODP · Mar 4, 2019 · Orthopedic

Device Facts

• Record ID: K190322
• Device Name: SCARLET® AC-T Secured Anterior Cervical Cage
• Applicant: Spineart
• Product Code: ODP · Orthopedic
• Decision Date: Mar 4, 2019
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

SCARLET® AC-T cages are indicated for use in skeletally mature patients with degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) of the cervical spine. Patients should have at least six (6) weeks of non-operative treatment with an intervertebral cage. SCARLET® AC-T cages are intended to be used at one level from the C2-C3 disc to the C7-T1 disc to facilitate intervertebral body fusion with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft. The SCARLET® AC-T Secured Anterior Cervical Cage is intended to be used as a standalone system used with the two bone screws provided and requires no additional supplementary fixation systems. When used without the two bone screws, SCARLET AC-T cages are to be used with supplemental fixation which has been cleared by the FDA for use in the cervical spine.

Device Story

SCARLET® AC-T is a box-shaped intervertebral spacer with a central cavity for bone graft; available in convex or lordotic profiles; multiple footprints and heights to accommodate patient anatomy. Device functions as a standalone system when used with two provided bone screws; alternatively, can be used with supplemental fixation. Used in cervical spine surgery to facilitate fusion. Surgeon implants device to stabilize disc space. Benefits include stabilization of the cervical spine and promotion of fusion in patients with degenerative disc disease.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on design features, technological characteristics, and risk analysis.

Technological Characteristics

Materials: Titanium alloy Ti6Al4V ELI (ISO 5832.3, ASTM F136). Form factor: Box-shaped spacer with central cavity. Fixation: Bone screws (3.0 mm and 3.5 mm diameters). Sterilization: Gamma radiation. Endotoxin limit: 20 EU/device (USP standard).

Indications for Use

Indicated for skeletally mature patients with cervical degenerative disc disease (discogenic neck pain) at one level (C2-C3 to C7-T1) who have failed at least 6 weeks of non-operative treatment. Used to facilitate intervertebral body fusion with bone graft.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• SCARLET® AC-T Secured Anterior Cervical Cage (K172065)
• SCARLET® AC-T Secured Anterior Cervical Cage (K143214)
• SCARLET® AC-T Secured Anterior Cervical Cage (K141314)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

March 4, 2019

SPINEART Franck Pennesi Chief Technical Officer 3 Chemin du Pre Fleuri Plan Les Ouates CH 1228 Geneva

Re: K190322

Trade/Device Name: SCARLET® AC-T Secured Anterior Cervical Cage Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: ODP, OVE Dated: February 11, 2019 Received: February 13, 2019

Dear Mr. Pennesi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You mav, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be avare that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

# Melissa Hall -S

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K190322

Device Name

SCARLET® AC-T Secured Anterior Cervical Cage

#### Indications for Use (Describe)

SCARLET® AC-T cages are indicated for use in skeletally mature patients with degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) of the cervical spine. Patients should have at least six (6) weeks of non-operative treatment with an intervertebral cage. SCARLET® AC-T cages are intended to be used at one level from the C2-C3 disc to the C7-T1 disc to facilitate intervertebral body fusion with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft.

The SCARLET® AC-T Secured Anterior Cervical Cage is intended to be used as a standalone system used with the two bone screws provided and requires no additional supplementary fixation systems. When used without the two bone screws, SCARLET AC-T cages are to be used with supplemental fixation which has been cleared by the FDA for use in the cervical spine.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| | <span> <span style="text-decoration: overline;">X</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> |
| | <span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> |

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

K190322 Page 1 of 2

## SPECIAL 510k DEVICE MODIFICATION Scarlet® AC-T

Image /page/3/Picture/2 description: The image shows the word "spineart" in a stylized font. The letters are black, and there is a purple butterfly above the "art" part of the word. There is a registered trademark symbol to the right of the word.

### 510(k) SUMMARY

| 510k | 510k SPECIAL - DEVICE MODIFICATION |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Reason for submission | Extension of the range of SCARLET® AC-T screws |
| Submitted by | SPINEART |
| | 3 Chemin du Pré Fleuri |
| | 1228 PLAN LES OUATES |
| | GENEVA SWITZERLAND |
| Contacts | Franck PENNESI Chief Technical Officer |
| | Phone: [phone] Fax: [phone] |
| | Mail: [e-mail] |
| | Regulatory contact: Dr Isabelle DRUBAIX (Idée Consulting) [e-mail] |
| Date Prepared | February 8, 2019 |
| Common Name | Intervertebral body fusion device |
| Trade Name | SCARLET® AC-T Secured Anterior Cervical Cage |
| Classification Name | Intervertebral fusion device with bone graft, cervical / Intervertebral fusion device |
| | with integrated fixation, cervical |
| Class | II |
| Product Code | ODP / OVE |
| CFR section | 888.3080 |
| Device panel | ORTHOPEDIC |
| Legally marketed<br>predicate devices | Primary predicate: SCARLET® AC-T Secured Anterior Cervical Cage (K172065)<br>manufactured by SPINEART |
| | Additional predicates: SCARLET® AC-T Secured Anterior Cervical Cage (K143214<br>and K141314) manufactured by SPINEART |

{4}------------------------------------------------

| Indications for use | SCARLET® AC-T cages are indicated for use in skeletally mature patients with<br>degenerative disc disease (defined as neck pain of discogenic origin with<br>degeneration of the disc confirmed by history and radiographic studies) of the<br>cervical spine. Patients should have at least six (6) weeks of non-operative<br>treatment prior to treatment with an intervertebral cage. SCARLET® AC-T cages are<br>intended to be used at one level from the C2-C3 disc to the C7-T1 disc to facilitate<br>intervertebral body fusion with autogenous bone graft and/or allogenic bone graft<br>comprised of cancellous and/or corticocancellous bone graft. |
|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | The SCARLET® AC-T Secured Anterior Cervical Cage is intended to be used as a<br>standalone system used with the two bone screws provided and requires no<br>additional supplementary fixation systems.<br>When used without the two bone screws, SCARLET AC-T cages are to be used with<br>supplemental fixation which has been cleared by the FDA for use in the cervical<br>spine. |
| Description<br>of<br>device | The Scarlet® AC-T is a box-shaped spacer with a central cavity that can be filled with<br>autogenous bone graft and/or allogenic bone graft comprised of cancellous and/<br>or corticocancellous bone graft to facilitate fusion. Scarlet® AC-T is available in<br>convex or lordotic profiles. Scarlet® AC-T comes in two footprints and six heights<br>in order to accommodate different patient anatomies. The Scarlet® AC-T fixation<br>screws are available with diameters 3.0 mm and 3.5 mm and come in various<br>sizes so as to accommodate different patient anatomies.<br>The SCARLET® AC-T spacer and screws are made of Titanium alloy Ti6Al4V ELI<br>conforming to ISO 5832.3 and ASTM F136. SCARLET® AC-T is single-use device<br>provided sterile (gamma radiation) and supplied with dedicated surgical<br>instruments.<br>Bacterial endotoxin testing as specified in USP standard is used for pyrogenicity testing<br>to achieve the Endotoxin limit of 20 EU / device. |
| Technological<br>characteristics<br>compared to<br>the<br>predicate devices | Added Scarlet® AC-T fixation screws are 3.5 mm in diameter with a core diameter of<br>2.1 mm for the first-intention screw and 2.6 mm for the revision screw. These added<br>Scarlet® AC-T fixation screws present a modified distal tip to facilitate the insertion<br>into the bone.<br>All other dimensions and features (material, hexalobe imprint, anti-backout<br>mechanism) are identical.<br>As was established in this submission added Scarlet® AC-T fixation screws are<br>substantially equivalent and has the same technological and mechanical characteristics<br>to predicate devices. |
| Discussion of Testing | No additional testing has been performed for the added Scarlet® AC-T fixation screws.<br>A risk analysis was performed to determine that additional testing was not needed. |
| Conclusion | Based on the design features, technological characteristics, feature comparisons,<br>indications for use, and non-clinical performance testing, the Scarlet® AC-T has<br>demonstrated substantial equivalence to the identified predicate devices. |